By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC Most of the titles in a biotech C-suite are generally self-explanatory. The Chief Technical and Manufacturing Officer runs operations in CMC and

The role of the core in making an organization great and how we do right by them By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Small organizations are amazing for the

Despite saving the world from COVID, pharma and biotech are still in the crosshairs of many politicians. With many anti-Pharma politicians and regulators emboldened in the current environment, and with more aggressive tax and spending policy in the works, there

Another quarter, another set of all-time highs for biotech funding – and this surfeit of capital continues raises possible concerns about its disciplined deployment. Back in January, when reflecting on the strange paradox of 2020, all-time-highs were across the board:

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace.  CEO’s that I have spoken

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC I’ve been thinking a lot about growth, and for good reason: Dyne is in the midst of a significant scale-up. We expanded our

By Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC In the fall of 2019, I wrote a blog called Ode to Patients.  As stresses from many directions have mounted over the past

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC.  If we could quantify the time and money impact of the resources invested in quarterly Board meeting preparation, I wonder if we would

Family Oddball, and a New Class of Safe Oral Autoimmune & Inflammatory Disease Treatment with Blockbuster Potential By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. On day one of the JPM

Just before I chaired a Board meeting last year, I spent a frustratingly painful hour going through many of the uncomfortable details of my divorce process and a set of emotional custody issues with my lawyers. Immediately after hanging up,

By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. This blog is dedicated to the front-line healthcare workers, essential service workers, scientists, patients, and their families who confront COVID-19 every day, and

2020 was an incredibly paradoxical year for those of us in biotech: the striking dichotomy of simultaneously experiencing agonizing tragedy alongside buoyant optimism. It was truly a horrifically tragic year for humanity, and for America in particular.  As everyone knows,